Use of dynamic contrast-enhanced MRI to assess the functional vascular pharmacokinetic parameters of normal human ovaries

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 47, Issue 2, 2002, Pages 107-114

  Hall, Glen H ^a   Atkin, Stephen L ^a   Turnbull, Lindsay W ^a  

^a HULL ROYAL INFIRMARY   (United Kingdom)

Author keywords

Dynamic contrast enhanced magnetic resonance imaging; Ovarian neoplasms; Ovary; Pharmacokinetics

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM PENTETATE; IGE SIGNA ECHOSPEED MR SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; SCOPOLAMINE;

ADOLESCENT; ADULT; ANGIOGENESIS; ARTICLE; ARTIFACT REDUCTION; BOLUS INJECTION; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; FEMALE; GYNECOLOGIC CANCER; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY DISEASE; OVARY TUMOR; PRIORITY JOURNAL; TUMOR DIAGNOSIS;

ADOLESCENT; ADULT; AGED; ARTERIES; CAPILLARY PERMEABILITY; CONTRAST MEDIA; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MENSTRUAL CYCLE; MIDDLE AGED; MUSCLE, SKELETAL; NEOVASCULARIZATION, PHYSIOLOGIC; OVARY; REFERENCE VALUES;

EID: 0036200281     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Dynamic MR imaging of the breast combined with analysis of contrast agent kinetics in the differentiation of primary breast tumours
2. Dynamic breast MR imaging: Are signal intensity time course data useful for differential diagnosis of enhancing lesions?
3. MR imaging of the breast
4. Tumor angiogenesis
5. Microvessel density in invasive breast cancer assessed by dynamic Gd-DTPA enhanced MRI
6. Angiogenic activity of cervical carcinoma: Assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome
7. Cyclic changes of vasculature and vascular phenotypes in normal human ovaries
8. Power and colour doppler ultrasonography for the evaluation of the vasculature of the human corpus luteum
9. Blood flow changes in the ovarian and uterine arteries during the normal menstrual cycle
10. Expression of vascular endothelial growth factor (VEGF) during folliculogenesis and corpus luteum formation in the human ovary
11. VEGF, VEGF-1, VEGF-2, microvessel density and endothelial cell proliferation in tumours of the ovary
12. In vivo neutralisation of vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF) inhibits ovarian carcinoma-associated ascites formation and tumor growth
13. Role of vascular endothelial cell growth factor in ovarian hyperstimulation syndrome
14. Normal ovaries and functional cysts: MR appearance
15. Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging
16. Angiogenin is involved in morphological changes and angiogenesis in the ovary
17. Serum vascular endothelial growth factor concentrations and ovarian stromal blood flow are increased in women with polycystic ovaries
18. Serum vascular endothelial growth factor and Doppler blood flow velocities in in vitro fertilisation: Relevance to ovarian hyperstimulation syndrome and polycystic ovaries
19. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome
20. Increased microvessel density in mucinous compared with malignant serous and benign tumours of the ovary
21. Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas
22. Neovasculature induced by Vascular Endothelial Growth Factor is fenestrated